Precigen (PGEN) Competitors

Precigen (NASDAQ:PGEN) and Disc Medicine (NASDAQ:IRON) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, community ranking, media sentiment, analyst recommendations, dividends, earnings and institutional ownership.

Does the MarketBeat Community believe in PGEN or IRON?

Precigen received 379 more outperform votes than Disc Medicine when rated by MarketBeat users. However, 86.76% of users gave Disc Medicine an outperform vote while only 67.49% of users gave Precigen an outperform vote.

Company	Underperform	Outperform
Precigen	Outperform Votes 438 67.49%	Underperform Votes 211 32.51%
Disc Medicine	Outperform Votes 59 86.76%	Underperform Votes 9 13.24%

Does the media refer more to PGEN or IRON?

In the previous week, Precigen had 13 more articles in the media than Disc Medicine. MarketBeat recorded 20 mentions for Precigen and 7 mentions for Disc Medicine. Disc Medicine's average media sentiment score of 0.65 beat Precigen's score of -0.11 indicating that Disc Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precigen	2 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Disc Medicine	6 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate PGEN or IRON?

Precigen currently has a consensus price target of $7.00, indicating a potential upside of 432.32%. Disc Medicine has a consensus price target of $98.80, indicating a potential upside of 104.05%. Given Precigen's higher possible upside, equities research analysts clearly believe Precigen is more favorable than Disc Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precigen	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
Disc Medicine	0 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	3.09

Which has more risk and volatility, PGEN or IRON?

Precigen has a beta of 1.82, suggesting that its share price is 82% more volatile than the S&P 500. Comparatively, Disc Medicine has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500.

Do insiders & institutionals believe in PGEN or IRON?

33.5% of Precigen shares are held by institutional investors. Comparatively, 83.7% of Disc Medicine shares are held by institutional investors. 44.9% of Precigen shares are held by company insiders. Comparatively, 4.2% of Disc Medicine shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Is PGEN or IRON more profitable?

Disc Medicine has a net margin of 0.00% compared to Precigen's net margin of -3,521.68%. Disc Medicine's return on equity of -25.24% beat Precigen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precigen	-3,521.68%	-123.06%	-87.33%
Disc Medicine	N/A	-25.24%	-23.96%

Which has higher earnings and valuation, PGEN or IRON?

Disc Medicine has lower revenue, but higher earnings than Precigen. Disc Medicine is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precigen	$3.93M	98.89	-$95.90M	-$0.56	-2.35
Disc Medicine	N/A	N/A	-$76.43M	-$3.92	-12.35

Summary

Disc Medicine beats Precigen on 10 of the 18 factors compared between the two stocks.